Comparison
Alpha-Lipoic Acid vs Epitalon
Side-by-side of Alpha-Lipoic Acid and Epitalon. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Alpha-Lipoic Acid
Alpha lipoic acid supplement guide: 600 mg/day oral dosing, R-ALA vs racemic absorption, neuropathy trial data, antioxidant mechanism, interactions.
Epitalon
Epitalon peptide (Epithalon, tetrapeptide AEDG): telomerase activation, lifespan extension data, anti-aging trials, dosage, half-life, and safety.
Effects at a glance
Alpha-Lipoic Acid
- •Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
- •Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
- •R-ALA enantiomer absorbs 40-100% better than racemic mixtures
- •Activates AMPK; produces small HbA1c reductions in T2DM
- •Plasma half-life ~30 minutes; split dosing or sustained-release is standard
- •Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required
Epitalon
- •Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the St. Petersburg Institute of Bioregulation
- •Russian clinical literature reports mortality reduction in elderly cohorts and improved melatonin output
- •Reported telomerase activation in human somatic cell culture and lifespan extension in mice and Drosophila
- •Independent Western replication is essentially absent; no FDA-standard RCTs
- •Anecdotal protocols use 5 to 10 mg subcutaneously daily for 10 to 20 day cycles, 2 to 4 times yearly
- •Not currently on the WADA Prohibited List
Side-by-side
| Attribute | Alpha-Lipoic Acid | Epitalon |
|---|---|---|
| Category | supplement | peptide |
| Also known as | ALA, thioctic acid, R-ALA, R-lipoic acid | Epithalon, Ala-Glu-Asp-Gly, AEDG, Epithalamin (precursor extract) |
| Half-life (hr) ↗ | 0.5 | 0.5 |
| Typical dose (mg) ↗ | 600 | 5 |
| Dosing frequency | 1 to 3 times daily on empty stomach | daily during cycle |
| Routes | oral, iv | subcutaneous, intramuscular, intranasal |
| Onset (hr) | 0.5 | 24 |
| Peak (hr) | 1 | 168 |
| Molecular weight | 206.33 | 390.35 |
| Molecular formula | C8H14O2S2 | C14H22N4O9 |
| Mechanism | Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes. | Synthetic tetrapeptide proposed to interact directly with DNA and chromatin to modulate tissue-specific gene expression. Reported effects include telomerase activation, increased melatonin output from pineal cells, and circadian normalization. |
| Legal status | Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany | Not FDA approved; registered in Russia under domestic pharmaceutical framework; research-use-only grey market in US/EU |
| WADA status | allowed | unknown |
| DEA / Rx | Not scheduled | Not scheduled (research chemical) |
| Pregnancy | Insufficient data; precautionary avoidance | Insufficient data; not recommended |
| CAS | 62-46-4 | 307297-39-8 |
| PubChem CID | 864 | 219042 |
| Wikidata | Q161227 | Q5384126 |
Safety profile
Alpha-Lipoic Acid
Common side effects
- nausea
- abdominal discomfort
- diarrhea
- sulfurous odor
- rash (rare)
Contraindications
- pregnancy and lactation (insufficient safety data)
- active insulin autoimmune syndrome predisposition
Interactions
- insulin and sulfonylureas: additive hypoglycemia; medication dose adjustment may be required(major)
- thyroid hormone: may reduce T4 to T3 conversion at high doses(moderate)
- biotin: ALA competes with biotin uptake; chronic use can induce biotin insufficiency(minor)
- iron supplements: ALA chelates iron and reduces absorption; separate dosing(moderate)
- chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)
Epitalon
Common side effects
- injection-site reactions
- occasional mild headache (rare)
Contraindications
- pregnancy
- lactation
- active malignancy (theoretical telomerase concern)
- concurrent immunosuppression
Interactions
- melatonin: potential additive effect on circadian and pineal output; no controlled data(minor)
Which Should You Take?
Alpha-Lipoic Acid comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Epitalon is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Alpha-Lipoic Acid.
- → If your priority is long-term neuroprotection, pick Alpha-Lipoic Acid.
- → If your priority is sleep onset or sleep quality, pick Epitalon.
- → If your priority is circadian regulation, pick Epitalon.
Edge case: If you want to avoid research-only / gray-market sourcing, Alpha-Lipoic Acid is the more accessible choice.
Default choice: Alpha-Lipoic Acid. Lower friction to source, and broader goal coverage. Reach for Epitalon only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Alpha-Lipoic Acid and Epitalon?
Alpha-Lipoic Acid and Epitalon differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Alpha-Lipoic Acid or Epitalon?
Alpha-Lipoic Acid half-life is 0.5 hours; Epitalon half-life is 0.5 hours.
Can you stack Alpha-Lipoic Acid with Epitalon?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper